Stock DNA
Pharmaceuticals & Biotechnology
INR 9,578 Cr ()
57.00
34
0.00%
0.00
0.00%
11.15
Total Returns (Price + Dividend) 
Sudeep Pharma for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
28-May-2026 | Source : BSESubmission of Earnings Call Transcript for Q4 FY26.
Compliances-Reg.24(A)-Annual Secretarial Compliance
27-May-2026 | Source : BSESubmission of Annual Secretarial Compliance Report for FY 2025-26
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23-May-2026 | Source : BSEPursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 as amended from time to time we herewith submit the participation of Company Officials in various Investor Conferences in Mumbai as annexed.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 14 Schemes (6.19%)
Held by 13 FIIs (1.55%)
Riva Resources Private Limited (40.35%)
Nuvama Crossover Opportunities Fund - Series Iii (3.42%)
3.11%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is -11.20% vs 2.73% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is -4.09% vs -9.65% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025
YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025